Gerresheimer at Pharmapack 2024

Looking for the right solution for your next drug blockbuster or biologics innovation?

Get insights on how we could support you with our best-in-class containment solutions and innovative drug delivery devices at Pharmapack 2024.

Visit our booth, browse our comprehensive product range or talk to our experts.

We are looking forward to seeing you!

January 24th - 25h, Paris Expo, Porte de Versailles - Hall 7.2 | Booth# F60

Meet our experts and get your ticket!

On the trade shows' ticket page please scroll down and use the "registration with your email" option below the blue “register” button and take the chance to get a free ticket.

Book a meeting Get your ticket

Innovation Track sponsored by Gerresheimer

Listen to our experts Mithun Ratnakumar and Oliver Haferbeck during the innovation track sponsored by Gerresheimer:

"Device & Packaging Innovation: Technical innovation, market dynamics and trends for product, packaging and device design"

Mithun Ratnakumar
Director Technology Strategy & Governance

Opportunities and Challenges in Connected Drug Delivery

Join us for an insightful discussion on 'Opportunities and Challenges in Connected Drug Delivery' The talk explores the current integration of digital health in drug delivery and various opportunities that it presents. Delving into the landscape of drug delivery, we examine the rise of connected devices, emphasizing the delicate balance between technology and compassionate care. This session also addresses real-world challenges like adoption, satisfaction, regulatory, and security considerations. Be part of the conversation on overcoming these challenges.

24, January, 11.00 - 11.10 h, Conference Theatre, Room 721

Oliver Haferbeck
Global Senior Vice President Innovation AT und CEO Sensile Medical AG

Overcoming challenges when developing subcutaneous drug delivery devices that empower patient self-administration.

The trend in parenteral patient therapy has been moving towards the home-care setting for some time as it empowers patient independence. However home administration brings additional requirements when developing a delivery device, and these are constantly evolving. Patient safety is always paramount, but useability is another critical factor, as well as sustainability and connectivity to support patient adherence. The challenge is to design a device to meet as many requirements as possible that can be on the market within 4-8 years. In this presentation we will discuss Gerresheimer’s mission of “innovating for a better life” and how we apply this when developing solutions that respond to the needs of patients, our pharmaceutical industry customers, and the environment, today and into the future.

24, January , 11.25 - 11.45 h, Conference Theatre, Room 721

Visit our Learning Lab Session

Gerresheimer's Product Platforms : designated quality levels to secure best in class performance in multiple application fields and demanding disease areas

Picking one example, we'll elaborate on our offering in the ophthalmology field.

As a solution provider with a unique & dedicated product portfolio, Gerresheimer is continuously exploring options to better accommodate their customers along the drug development and drug LCM journey.

With its newly installed product platforms, Gerresheimer will be combining outstanding quality levels with specific product requirements in dedicated application fields and disease areas.

From dental care over hematology, vaccines, diabetes and metabolism disorders into complex and more demanding areas such as Cell Gene Therapy, ophthalmology and oncology ...

24, January, 15.50 - 16.20 h, Learning Lab Theatre L20

Stefan Verheyden
Global Vice President Biological Solutions and Syringes

Holger Krenz
Global Vice President Business Development High Value Products Tubular Glass

Joint Session with Sterigenics

Prefilled ophthalmic syringes - New possibilities in terminal sterilization

Eric Offermann and Bernd Zeiss will speak about Nitrogen Dioxide (NO2) as a new sterilization method and an alternative to EtO gas. A joint study carried out by Gerresheimer, Sterigenics and Früh, showed that NO2 is well suited to terminally sterilize prefilled ophthalmic syringes. The following 5 topics will be addressed in detail:

Comparison of EtO vs. NO2 penetration into the filled syringe.
Analyze gas ingress through 4 different plunger stoppers including silicone oil-free and standard rubber plungers.
Scrutinize gas ingress through 2 different cap designs based on different elastomer properties.
Investigate gas permeation through COP plastic barrels compared to glass.
Check if the final blister has an influence on either sterilization method.

The ultimate objective of this study was to offer the best syringe design and packaging paired with the most suitable sterilization modality to pharma customers.

25, January, 10.10 - 10.40 h, Learning Lab Theatre L20